Helix biotech startup GlycanAge secures $4.2m in seed funding

GlycanAge, a pioneering company specialising in cutting-edge biotechnology has successfully completed its $4.2 million seed funding round, to revolutionise personalised preventative care.

With its HQ based in The Catalyst here at Newcastle Helix, GlycanAge offers a test that measures biological age, providing insight into how lifestyle and the environment are influencing the aging process, to enable early prevention strategies for both consumers and healthcare professionals.

The investment success of GlycanAge is a testament to the thriving biotech sector in the region and the vibrant innovation ecosystem flourishing within Newcastle Helix.

John Seager, Estates Director, Newcastle Helix, said: "We are thrilled to see GlycanAge's success in securing investment, as it exemplifies the innovative spirit and collaborative ethos of Newcastle Helix. As a home to innovative science and technology knowledge-based, data-led organisations tackling society's most pressing challenges, including ageing, Newcastle Helix is proud to be at the forefront of driving positive change.This achievement underscores the Helix partnership’s commitment to creating growth opportunities for businesses and investors as we collectively strive to build a brighter and more sustainable future."

The landscape of glycobiology is changing rapidly, with breakthroughs in technology that underscore the immense promise of glycobiology in predicting diseases, guiding interventions, and tailoring therapies. The additional investment will allow the company to expand into the broader diagnostics market.

Nikolina Lauc, CEO of GlycanAge, said: "We are thrilled to have the support of LAUNCHub Ventures and Kadmos Capital, who share our vision for a healthier future. This funding round marks a significant milestone for GlycanAge, and we are excited to continue our journey towards transforming healthcare and empowering individuals to take control of their well-being."

The $4.2 million seed funding round was led by venture capital fund LAUNCHub Ventures and UK-based deep-tech fund Kadmos Capital.

LAUNCHub Ventures is a leading early-stage venture capital fund focused on technology startups in Central and South Eastern Europe (SEE & CEE), and diaspora founders based in global technological hubs. Kadmos Capital is a London-based Venture Capital firm focused on early stage investments in deep tech and impactful technologies. The fund focuses on three main sectors; TechBio, AI & Data and Sustainability.

Fox Williams advised GlycanAge on its $4.2 million fundraising.